Compugen Ltd.
NASDAQ:CGENBiotechnology
Healthcare
$1.96 +0.50%
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
52W Low $1.30High $3.24
Volume 0.15M
Average 0.48M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$31.63M
FY 2025 · Annual
-36.2% YoYInvesting Cash Flow
$30.00M
FY 2025 · Annual
Financing Cash Flow
$10.60M
FY 2025 · Annual
+1814.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.28M | 4.33M | 3.55M | 3.02M | 0 |
| Change in Working Capital | 6.82M | (5.55M) | (20.71M) | 62.05M | (5.35M) |
| Accounts Receivables | 2M | 3.04M | (61.11M) | 59.93M | 360K |
| Inventory | (3.37M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.37M | (1.6M) | 3.51M | (4.41M) | 517K |
| Other Working Capital | 3.79M | (7M) | 36.9M | 6.53M | (6.23M) |
| Other Non-Cash Items | (573K) | 515K | (452K) | (1.72M) | 1.16M |
| Operating Cash Flow | (22.75M) | (34.51M) | (35.89M) | 49.6M | 31.63M |
| Capital Expenditures | (292K) | (487K) | (172K) | (118K) | (306K) |
| Acquisitions (Net) | 3K | 2K | 0 | 0 | 1K |
| Purchases of Investments | (129.95M) | (76.9M) | (53.71M) | (159.75M) | (96.07M) |
| Sales of Investments | 136.85M | 114.45M | 89.39M | 113.95M | 126.37M |
| Other Investing Activities | 0 | 0 | 0 | (329K) | 0 |
| Investing Cash Flow | 6.62M | 37.06M | 35.51M | (46.25M) | 30M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 14.96M | 353K | 3.08M | 544K | 10.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.88M | 0 | 0 | 10K | (4K) |
| Financing Cash Flow | 16.84M | 353K | 3.08M | 554K | 10.6M |
| Effect of Forex Changes | 469K | (584K) | 129K | 68K | 135K |
| Net Change in Cash | 704K | 2.91M | 2.83M | 3.97M | 72.37M |
| Free Cash Flow | (23.04M) | (34.99M) | (36.06M) | 49.49M | 31.33M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$35.3M
+ D&A$475.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$5.3M
+ Other Non-Cash$1.2M
= Operating Cash Flow$31.6M
- Capex-$306.0K
= Free Cash Flow$31.3M
Analysis
FY2025 free cash flow is $31.3M. FCF conversion is 88.6% of net income. Operating cash flow was $31.6M, with capex of -$306.0K. The largest bridge item is Working Capital at -$5.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Sep 10, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 6-K | 6-K filing | Aug 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 30, 2026 |
Does CGEN generate free cash flow?
Compugen Ltd. (CGEN) generated $31.33M of free cash flow in fiscal 2025.
How much operating cash flow does CGEN produce?
Operating cash flow was $31.63M, before capital expenditures of $306,000.00.
Continue the stock analysis
Jump to another research area for this company.